Searchable abstracts of presentations at key conferences in endocrinology

ea0049ep831 | Adrenal cortex (to include Cushing's) | ECE2017

ACTH-independent subclinical Cushing’s syndrome in patient with acromegaly and adrenal incidentaloma

Kurowska Maria , Malicka Joanna , Tarach Jerzy

Introduction: It is well established that acromegaly is associated with increased risk of cancer. However, it is currently unclear whether patients with acromegaly are at increased risk of developing adrenal tumors and little is known about the association between acromegaly and adrenal adenomas. The simultaneous occurrence of preclinical Cushing’s syndrome in patients with acromegaly and adrenal adenoma is extremely rare, and to our knowledge, so far only 5 such cases ha...

ea0049ep850 | Clinical case reports - Pituitary/Adrenal | ECE2017

Temozolomide alone or in combination with bevacizumab and capecitabine in the treatment of atypical pituitary adenomas – own experience

Kurowska Maria , Malicka Joanna , Tarach Jerzy

Introduction: Atypical pituitary adenomas are tumors refractory to conventional therapy and characterized by a tendency to rapid progression and high recurrence rate. The aim of the study was to summarize our experience in treatment of atypical pituitary adenomas with temozolomide (TMZ).Material: 5 patients (3F;2M) aged 44–58 (mean 52.4±5.4) years treated in 2013–2016. We analyzed the results, tolerance and side effects of TMZ.<p class...

ea0059p069 | Clinical practice, governance &amp; case reports | SFEBES2018

Patient perception of provision of care for multiple endocrine neoplasia disorders in the UK compared to other EU member states

Grey Joanna , Breugmann Petra , Newey Paul

We report the results of the first Europe-wide survey of patients with multiple endocrine neoplasia (MEN) disorders by the European MEN Alliance (EMENA). METHOD: An online questionnaire was distributed via patient groups, social media and health professionals. A total of 284 responses were analysed. RESULTS: 35% (n=99) UK responses and 65% (n=185) from 17 other EU countries: 68% female, 32% male (UK; 75% and 25%). Disorders represented were: MEN1 n=2...

ea0059p072 | Clinical practice, governance &amp; case reports | SFEBES2018

Patient perception of quality of care for multiple endocrine neoplasia disorders in the UK compared to other EU countries

Grey Joanna , Bruegmann Petra , Newey Paul

We report the results of the first Europe-wide survey of the Quality of Care of patients with multiple endocrine neoplasia (MEN) disorders by the European MEN Alliance (EMENA).Method: An online questionnaire was distributed via patient groups, social media and health professionals. A total of 284 responses were analysed.Results: 35% (n=99) of responses were from UK patients and 65% (n=185) from 17 other EU countri...

ea0037ep776 | Pituitary: clinical | ECE2015

High diversity of Cushing's disease in patients with corticotrophic macroadenoma

Kurowska Maria , Malicka Joanna , Tarach Jerzy S

Introduction: In 7–20% of cases, Cushing’s disease is due to ACTH-producing macroadenoma. Aim of the study was to present our observations concerning etiologic, clinical, and therapeutic diversity of Cushing’s disease in patients with macrocorticotropinomas.Material and methods: Retrospective analysis of medical records of nine patients (5F; 4M) hospitalized in 2002–2015.Results: Four of the patients (2F; 2M) we...

ea0037ep1264 | Clinical Cases–Thyroid/Other | ECE2015

Severe hyponatremia in the course of autoimmune polyglandular syndrome type 2 of atypical clinical picture

Kurowska Maria , Malicka Joanna , Jerzy , Tarach Stanislaw

Introduction: Severe hyponatremia defined as the blood sodium concentration below 115 mmol/l is rarely recognised in the course of autoimmune polyglandular syndrome type 2 (APS t.2). The aim of the paper is to present the female patient with severe hyponatremia preceding the diagnosis of APS t.2 of atypical clinical picture.Case report: A 54-year-old woman with the diagnosis of psoriasis established 10 years earlier and treated for psoriatic arthritis fr...

ea0035p79 | Bone and Osteoporosis | ECE2014

Renal aspects of primary hyperparathyroidism

Szymczak Jadwiga , Bohdanowicz-Pawlak Anna , Jakubowska Joanna

Introduction: Nephrolithiasis and bone disease are the most common complications of primary hyperparathyroidism (PHPT). The aim of this study was to evaluate the relationships between the existence of kidney stones, renal function and bone mineral density (BMD) in PHPT.Description of methods/design: Biomedical evaluation, BMD measurements and renal ultrasonography were performed in a group of 75 consecutive PHPT patients aged 57.6±12.7 years. The co...

ea0035p227 | Clinical case reports Pituitary/Adrenal | ECE2014

Meningitis coexisting with pituitary macroadenoma: report of two cases

Malicka Joanna , Kurowska Maria , Tarach Jerzy S

Background: Meningitis coexisting with pituitary macroadenoma is rarely observed. It occurs either as a primary meningitis (primary tumor manifestation), or as a secondary meningitis (after neurosurgery or reduction of the volume of the tumor which has destroyed the sellar floor or the skull base).Objective: Case reports of two patients with the concomitance of secondary meningitis and pituitary macroadenoma.Case 1: A 36-year-old m...

ea0058oc8.2 | Oral Communications 8 | BSPED2018

The effect of GnRHa treatment on bone density in young adolescents with gender dysphoria: findings from a large national cohort

Joseph Tobin , Ting Joanna , Butler Gary

Background/Aims: More young people with gender dysphoria are undergoing hormonal intervention with GnRHa treatment. The impact on bone density is not known in the very young transgender adolescents, with guidelines mentioning that Bone Mineral Density (BMD) should be monitored without a suggestion on how. This study aimed to investigate whether there were any changes in BMD or Bone Mineral Apparent Density (BMAD) whilst on GnRHa therapy.Methods: A retros...

ea0020p192 | Endocrine tumours and neoplasia | ECE2009

The comparison of serum endostatin levels between patients with metastatic and non-metastatic well differentiated thyroid cancer

Klubo-Gwiezdzinska Joanna , Roman Junik , Ewa Kopczynska

Tumor growth is limited by its neoangiogenesis, which is dependent on dynamic balance beetween it’s activators and inhibitors. One of the most important antiangiogenic factor is endostatin. Therefore we hypothesized, that serum endostatin concentration would differ between patients with metastatic and non-metastatic thyroid cancer, with multinodular goiter and healthy subjects. We also hypothesized that endogenous TSH stimulation would effect serum endostatin level.<p...